search
Back to results

VEST III PMS Clinical Protocol (VEST III)

Primary Purpose

Coronary Artery Disease

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
VEST External Support
Coronary Artery Bypass Surgery
Sponsored by
Vascular Graft Solutions Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient scheduled for on-pump CABG on clinical grounds
  2. Two or more bypass vein grafts bypasses indicated as follows: one (1) for right coronary artery, 1 or more for left coronary arteries and IMA indicated for the LAD on clinical grounds
  3. Appropriately sized and accessible target coronary arteries, with a minimum diameter of 1.5 mm and adequate vascular bed
  4. Ability to give their informed written consent
  5. Ability and willingness to comply with study follow up requirements
  6. Patient is ≥ 18 and ≤ 80 years of age, and has Life expectancy ≥5 years

Exclusion Criteria:

  1. Concomitant non-CABG cardiac procedure
  2. Prior cardiac surgery
  3. Emergency CABG surgery (cardiogenic shock, inotropic pressure support, IABP)
  4. Contraindication for on-pump CABG with cardioplegic arrest (e.g. severely calcified aorta)
  5. Calcification at the intended anastomotic sites, as assessed upon opening of the chest, before randomization
  6. Severe vein varicosity
  7. Prior debilitating stroke less than 1 year before surgery
  8. Severe renal dysfunction (Cr>2.0 mg/dL or >177 μmol/L)
  9. Women of child bearing age
  10. Concomitant life-threatening disease likely to limit life expectancy to less than 5 years
  11. Indication for Warfarin up to time of surgery
  12. Inability to tolerate or comply with required normal post-operative drug regimen (antiplatelet, statin and beta-blockers) that cannot adequately be controlled.
  13. inability to take aspirin
  14. Contraindication to intravascular contrast material that cannot be adequately controlled with pre-medication
  15. Inability to comply with required follow-ups including angiographic and/or CT imaging methods.
  16. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study

Sites / Locations

  • Medical University of Innsbruck
  • Medical University of Vienna
  • German Heart Center
  • Immanuel Hospital Bernau. Brandenburg Heart Center
  • University Hospital of Cologne
  • West-German Heart Center Essen University
  • University Medical Center Schleswig-Holstein
  • Krankenhaus der Barmherzigen Bruder
  • Rambam - Health Care Campus
  • Sheba Medical Center Hospital
  • Papworth Hospital
  • Blackpool Victoria Hospital
  • University Hospitals Bristol
  • The John Radcliffe Hospital
  • University Hospital Southampton

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

VEST supported

Control

Arm Description

Vein graft supported by VEST

Vein grafts unsupported by VEST

Outcomes

Primary Outcome Measures

Proportion of Vein grafts with Fitzgibbon I patency score out of all grafts including occluded ones.
Perfect patency, no lumen irregularities. Rates out of all grafts including occluded ones.

Secondary Outcome Measures

Intimal hyperplasia area
Sub group (IVUS) - Intimal hyperplasia (plaque+media) area [mm2] as assessed by IVUS
MACCE
Composite of: All-cause mortality; Stroke; Myocardial infarction; Coronary revascularization
Vein graft failure
Defined as ≥50% stenosis by QCA
Early vein graft failure
Early vein graft failure, defined as >50% occlusion by CT Angio

Full Information

First Posted
July 25, 2015
Last Updated
June 23, 2020
Sponsor
Vascular Graft Solutions Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02511834
Brief Title
VEST III PMS Clinical Protocol
Acronym
VEST III
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
October 19, 2015 (Actual)
Primary Completion Date
June 2019 (Actual)
Study Completion Date
October 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vascular Graft Solutions Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Post marketing surveillance (PMS) study. 200 patients will be enrolled in a prospective, multi center, randomized, two-arm, open label, and controlled, enrolling patients with multi vessel atherosclerotic coronary artery disease, scheduled to undergo Coronary artery bypass grafting (CABG) with arterial grafting of IMA to LAD, one saphenous vein graft (SVG) to the right territory and one or more SVGs to the left territory. Of all vein grafts, one will be selected randomly to receive treatment with VEST and another designated Control.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
184 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VEST supported
Arm Type
Experimental
Arm Description
Vein graft supported by VEST
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Vein grafts unsupported by VEST
Intervention Type
Device
Intervention Name(s)
VEST External Support
Intervention Type
Procedure
Intervention Name(s)
Coronary Artery Bypass Surgery
Other Intervention Name(s)
CABG
Primary Outcome Measure Information:
Title
Proportion of Vein grafts with Fitzgibbon I patency score out of all grafts including occluded ones.
Description
Perfect patency, no lumen irregularities. Rates out of all grafts including occluded ones.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Intimal hyperplasia area
Description
Sub group (IVUS) - Intimal hyperplasia (plaque+media) area [mm2] as assessed by IVUS
Time Frame
2 years
Title
MACCE
Description
Composite of: All-cause mortality; Stroke; Myocardial infarction; Coronary revascularization
Time Frame
2 years
Title
Vein graft failure
Description
Defined as ≥50% stenosis by QCA
Time Frame
2 years
Title
Early vein graft failure
Description
Early vein graft failure, defined as >50% occlusion by CT Angio
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient scheduled for on-pump CABG on clinical grounds Two or more bypass vein grafts bypasses indicated as follows: one (1) for right coronary artery, 1 or more for left coronary arteries and IMA indicated for the LAD on clinical grounds Appropriately sized and accessible target coronary arteries, with a minimum diameter of 1.5 mm and adequate vascular bed Ability to give their informed written consent Ability and willingness to comply with study follow up requirements Patient is ≥ 18 and ≤ 80 years of age, and has Life expectancy ≥5 years Exclusion Criteria: Concomitant non-CABG cardiac procedure Prior cardiac surgery Emergency CABG surgery (cardiogenic shock, inotropic pressure support, IABP) Contraindication for on-pump CABG with cardioplegic arrest (e.g. severely calcified aorta) Calcification at the intended anastomotic sites, as assessed upon opening of the chest, before randomization Severe vein varicosity Prior debilitating stroke less than 1 year before surgery Severe renal dysfunction (Cr>2.0 mg/dL or >177 μmol/L) Women of child bearing age Concomitant life-threatening disease likely to limit life expectancy to less than 5 years Indication for Warfarin up to time of surgery Inability to tolerate or comply with required normal post-operative drug regimen (antiplatelet, statin and beta-blockers) that cannot adequately be controlled. inability to take aspirin Contraindication to intravascular contrast material that cannot be adequately controlled with pre-medication Inability to comply with required follow-ups including angiographic and/or CT imaging methods. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study
Facility Information:
Facility Name
Medical University of Innsbruck
City
Innsbruck
Country
Austria
Facility Name
Medical University of Vienna
City
Vienna
Country
Austria
Facility Name
German Heart Center
City
Berlin
Country
Germany
Facility Name
Immanuel Hospital Bernau. Brandenburg Heart Center
City
Bernau
Country
Germany
Facility Name
University Hospital of Cologne
City
Cologne
Country
Germany
Facility Name
West-German Heart Center Essen University
City
Essen
Country
Germany
Facility Name
University Medical Center Schleswig-Holstein
City
Lübeck
Country
Germany
Facility Name
Krankenhaus der Barmherzigen Bruder
City
Trier
Country
Germany
Facility Name
Rambam - Health Care Campus
City
Haifa
Country
Israel
Facility Name
Sheba Medical Center Hospital
City
Ramat Gan
Country
Israel
Facility Name
Papworth Hospital
City
Papworth Everard
State/Province
Cambridge
Country
United Kingdom
Facility Name
Blackpool Victoria Hospital
City
Blackpool
Country
United Kingdom
Facility Name
University Hospitals Bristol
City
Bristol
Country
United Kingdom
Facility Name
The John Radcliffe Hospital
City
Oxford
Country
United Kingdom
Facility Name
University Hospital Southampton
City
Southampton
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
29373645
Citation
Amin S, Werner RS, Madsen PL, Krasopoulos G, Taggart DP. Influence of external stenting on venous graft flow parameters in coronary artery bypass grafting: a randomized study. Interact Cardiovasc Thorac Surg. 2018 Jun 1;26(6):926-931. doi: 10.1093/icvts/ivy007.
Results Reference
derived

Learn more about this trial

VEST III PMS Clinical Protocol

We'll reach out to this number within 24 hrs